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Epidermolysis bullosa (EB), a group of
heritable skin fragility disorders, is char-
acterized by blistering, erosions, and
chronic ulcers of the skin and mucous
membranes, associated with extracuta-
neous manifestations with considerable
morbidity and mortality. Mutations in
as many as 18 distinct genes are known
to underlie different EB-like disorders.
The progress in molecular genetics of
this group of disorders has improved the
accuracy of diagnostic subclassification
and prognostication, and has formed the
basis for prenatal and preimplantation
genetic diagnosis. Quite recently,
inroads have also been made toward
the treatment of EB by gene therapy,
protein replacement, and cell-based
approaches. DEBRA International, the
premiere patient-advocacy organiza-
tion, sponsored the Triennial Research
Conference in November 2012 in
Marbella, Spain*. This Conference
Report summarizes the presentations
and discussions of this meeting, with
emphasis on the most recent progress
in EB research over the past 3 years.
Introduction
EB, a group of disorders characterized
by excessive fragility of the skin,
in association with a number of extra-
cutaneous manifestations, presents with
blistering and erosions with consider-
able morbidity and mortality (Fine et al.,
2008; Fine and Mellerio, 2009). EB is
clearly a rare disease, as defined by
fewer than 200,000 patients in the
United States; less than 5 patients per
10,000 inhabitants in the European
Union; and fewer than 50,000 affected
individuals in Japan. Nevertheless,
the estimated incidence of B1:20,000
implies that there are as many as 30,000
affected individuals in the United
States, and over half a million patients
worldwide with the diagnosis of EB
(Uitto, 2012). EB has served as a
prototype of heritable skin diseases in
which significant progress has been
made over the past few decades from
a condition defined purely by clinical
description to an entity with profound
understanding of the molecular defects
at the genomic level (Table 1). Most
recently, this progress on EB has culmi-
nated in early clinical trials of different
molecular approaches for treatment and
potential cure (Uitto et al., 2012).
The leading EB researchers from
laboratories and hospitals around
the world convened by invitation in
November 2012 at Marbella, Spain, to
discuss the state of the art of EB research
(Figure 1). The goals of this DEBRA
2012 Research Conference were as
follows: (1) to review the prospects of
fundamental EB research and identify
challenges in the development of clin-
ical solutions; (2) to identify unexplored
opportunities from relevant research in
complementary areas; and (3) to derive
a community consensus on EB research
and therapy development priorities.
The authors of this report were
members of the organizing committee;
Drs Leena Bruckner-Tuderman (Freiburg
University) and Jouni Uitto (Thomas
Jefferson University) served as the
co-chairs of the conference, and the
program, together with speakers and
session chairs, is in Supplementary
Table S1 online. The proceedings of this
international research meeting are sum-
marized here with emphasis on advances
made since the previous triennial meet-
ing in 2009 (Uitto et al., 2010).
New phenotypes, novel genes
EB was initially recognized as a distinct
diagnostic entity over a century ago, and
the ensuing decades witnessed the iden-
tification of diverse phenotypes, which
resulted in suggestions that there are
over 30 clinical variants (Gedde-Dahl,
1986) (Table 1). The molecular era of EB
research was initiated in the early
1990s, and within a few years as many
as 10 distinct genes were shown to
harbor mutations in the classic forms
of EB (Table 2). More recently, a number
of additional conditions manifesting
with fragility of the skin, often in com-
bination with extracutaneous findings,
have been included in the spectrum of
EB (Table 3). Thus, the total number of
genes harboring mutations in various
diseases in the spectrum of EB is now
at least 18.
Model systems to study EB
The understanding of the pathomechan-
isms has been greatly facilitated by a
number of model systems for various
forms of EB. Of particular value have
been genetically engineered mouse
models and identification of spontaneous
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EB phenotypes both in domestic and
wild animals. Since the last update
(Bruckner-Tuderman et al., 2010),
several new animal models have been
developed. For example, new mouse
models for junctional EB (JEB) with
reduced expression of the laminin g2
chain (Bubier et al., 2010; Adair-Kirk
et al., 2012) bring significant advantages
over the existing knockout models for
Herlitz JEB, which have been of
limited use because of early lethality
(Meng et al., 2003). In one of them, a
spontaneous mutation in the Lamc2
gene generates a hypomorphic allele
and low levels of laminin-332 at the
basement membrane zone (Bubier et al.,
2010). The mutant mice survive and
exhibit progressive skin blistering
and extracutaneous features of vari-
able severity; ultrafine recombination
mapping unambiguously identified type
XVII collagen as a major genetic
modifier of the strength of dermal–
epidermal adhesion and provided an
example of how naturally occurring
genetic variation can act in epistasis to
impact the severity of JEB (D. Roope-
nian, poster presentation in EB2012).
In another model, a doxycycline-con-
trollable human laminin g2 transgene
was expressed in mice on the Lamc2
knockout background (Adair-Kirk et al.,
2012). As long as doxycycline was
included in the diet, the expression
of human laminin-332 rescued the
phenotype, but when doxycycline was
withdrawn the mice developed trauma-
induced skin blistering similar to human
JEB. This mouse model will be valuable
for testing novel biologically valid
therapies for JEB.
In DEB, a clinical understanding of
disease mechanisms has also been
advanced by new animal models.
For example, clinical observations of
chronic wounds in recessive dystrophic
EB (RDEB) have suggested delayed
wound closure, but no experimental
data for this have existed so far.
Controlled studies on wound healing
using two different mouse models, the
type VII collagen hypomorph and
tamoxifen-mediated inactivation of the
Col7a1 gene, demonstrated that the loss
of type VII collagen impairs early wound
healing. Analysis of the dental pheno-
type in a mouse expressing human type
VII collagen on the Col7a1 / back-
ground (Umemoto et al., 2012) revealed
that the loss of type VII collagen
hampers differentiation of ameloblasts
and leads to defective enamel forma-
tion, which can be corrected by
expressing human type VII collagen in
the Col7a1-deficient mouse.
A spontaneous RDEB in Golden retrie-
ver dogs results from the homozygous
Col7a1 mutation p.G1906S (Gache
et al., 2011). Affected pups exhibit
cutaneous and mucosal blistering,
scarring, and dystrophy, as well as loss
of nails. This relatively large animal
model has been useful for testing the
correction of dermal–epidermal dysadhe-
sion using genetically modified epider-
mal grafts (Gache et al., 2011) and for
testing protein replacement therapy.
Recently, the first animal model
for dominant DEB was discovered.
Rats carrying a spontaneous hetero-
zygous glycine substitution mutation in
Table 1. Decades of diagnostics and research on EB with selected
milestones
Decades Milestones and achievements
1880s Recognition of EB as a clinically distinct entity
1900–1950s Expansion of the clinical subsets by recognition of defined phenotypes
1960s Recognition of three major subtypes—simplex, junctional, and dystrophic
1970–1980s Early biochemical observations on disease pathomechanisms
1990s Identification of genetic mutations in candidate genes with diagnostic implications,
establishment of DNA-based prenatal testing, and preimplantation genetic diagnosis
2000s Development of preclinical model systems and early proof-of-principle clinical trials
2010s Implementation of phase I/II clinical trials for EB
Abbreviation: EB, epidermolysis bullosa.
Figure 1. Participants of the DEBRA International Research Conference 2012 in Marbella, Spain.
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type VII collagen develop fragile and
blister-prone skin as a consequence of
functional abnormalities of the anchor-
ing fibrils. The model recapitulates the
features of human DDEB but, as in
patients, the animals exhibit individual
variations in the disease manifestations
(Nystro¨m et al., 2013). Thus, this model
may be well suited to analyze the effects
of modifier genes in DEB.
Pathobiological disease mechanisms
In vitro cell culture systems have also
been valuable for unraveling pathobio-
logical disease mechanisms in EB.
Intriguing novel evidence continues to
emerge to indicate that the abundance
of type VII collagen is not the
only determinant of disease severity in
DEB, but a host of other differentially
expressed genes contribute to the phe-
notypes. For example, disease proteo-
mics using normal and RDEB fibroblasts
showed that the loss of type VII collagen
affects a number of other proteins
involved in the maintenance of base-
ment membranes and the extracellular
matrix in the skin (Ku¨ttner et al., 2013).
In this context, an interesting phenotypic
modification was observed in
monozygotic twins with RDEB and
with identical COL7A1 mutations, but
with very different clinical mani-
festations. Several genes associated
with the inhibition of TGF-b pathways
were found to be differentially
expressed in dermal fibroblasts of these
twins, and are likely to explain the
variable disease severity in the twins
(Di Salvio et al., 2012).
An in vitro skin tumor model con-
structed with COL7A1 short-hairpin
RNA-treated keratinocytes indicated
that the loss of type VII collagen leads
to enhanced angiogenesis, as evidenced
by increased vascular endothelial
growth factor and thrombospondin
expression in the dermal compartment
(Martins et al., 2012). The activation
of stromal fibroblasts is controlled by
JAK signaling, and the cancer-associated
fibroblast-induced tumor invasion
by collaboration of JAK and ROCK
signaling (Sanz-Moreno et al., 2011),
suggesting that inhibitors of these
pathways could have potential as
anticancer agents in RDEB (C.
Gaggioli, personal communication).
A fibrin-based bioengineered human
skin is another intriguing in vitro/in vivo
model for understanding disease
mechanisms and for testing novel
therapies (Carretero et al., 2011). It can
be regenerated by orthotopic grafting
onto the back of immunodeficient
mice. Using patients’ keratinocytes and
fibroblasts, the system has permitted
modeling of EB and other monogenic
and acquired skin diseases. In addition,
various gene and cell therapy appr-
oaches for ex vivo correction of cells
have proved effective in this model,
which holds promise for optimized
testing of new therapeutic approaches
(Carretero et al., 2011).
Squamous cell carcinoma as a
complication of EB
Squamous cell carcinomas (SCCs)
represent the major cause of mortality
in individuals with RDEB (490% by the
age of 55 years; Fine et al., 2009). Thus,
there remains a critical need to improve
the understanding of the pathomecha-
nisms of SCC in RDEB, as well as
to develop novel diagnostic bio-
markers and therapeutic approaches. To
that end, some new findings on the
pathophysiology of SCC in RDEB have
emerged from studies focusing on both
DNA mutations in keratinocytes and
the influence of RDEB SCC–associated
fibroblasts.
Recently, cutaneous SCCs have been
shown to harbor the highest relative
burden of DNA mutations among all
Table 2. The classic variants of EB
Category
Level of blistering/
mutated genes
Simplex Basal cells
EBS KRT5, KRT14
EBS-PA PLEC
EBS-MD PLEC
Junctional Lamina lucida
HJEB, NHJEB LAMA3, LAMB3, LAMC2
NHJEB BPAG2/COL17A1
JEB-PA ITGA6, ITGB4
Dystrophic Sub-lamina densa
DDEB COL7A1
RDEB COL7A1
Abbreviations: DDEB, dominant dystrophic EB;
EB, epidermolysis bullosa; EBS, EB simplex;
EBS-MD, EBS with muscular dystrophy; EBS-
PA, EBS with pyloric atresia; HJEB, Herlitz
junctional EB; NHJEB, non-Herlitz junctional
EB; RDEB, recessive dystrophic EB.
Table 3. Rare variants of EB-like blistering disorders with known gene defects
Clinical entity1 Level of blistering Mutated genes/proteins Reference
Ectodermal dysplasia–skin fragility syndrome Suprabasal PKP1/plakophilin 1 (McGrath et al., 1997)
Kindler syndrome Mixed KIND1/kindlin 1 (Jobard et al., 2003;
Siegel et al., 2003)
Laryngo–onycho–cutaneous syndrome Lamina lucida LAMA3 A (LAMA3A)/laminin a3a (McLean et al., 2003)
Lethal acantholytic EB Suprabasal DSP/desmoplakin (Jonkman et al., 2005)
EBS, other Basal keratinocytes DST/BPAG1 (epithelial isoform) (Groves et al., 2010)
Acral peeling skin syndrome Suprabasal TGM5/transglutaminase-5 (Kiritsi et al., 2010)
Blistering±cardiomyopathy Suprabasal JUP/plakoglobin (Pigors et al., 2011)
EB-congenital nephrotic syndrome-interstitial lung disease Mixed ITGA3/integrin a3 (Has et al., 2012)
Trauma-induced skin blistering (AR) Lower epidermis EXPH5/exophilin-5 (Slac2-b) (McGrath et al., 2012)
Abbreviations: EB, epidermolysis bullosa; EBS, EB simplex.
1The inheritance of these conditions is autosomal recessive.
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human cancers, with 475% of non-
RDEB tumors containing mutations in
NOTCH1 or NOTCH2 (Wang et al.,
2011). The same study also identified
NOTCH1 mutations in two of three
RDEB SCCs, indicating that these may
be shared findings in RDEB as well as in
common UV irradiation–associated
SCCs in the general population. Further
research has also shown a lack of RAS
mutations in SCC in RDEB (0/6 samples)
(Pourreyron et al., 2007), but the
presence of some mutations in TP53
(3/8 SCCs) and CDKN2A promoter
methylation (2/8 SCCs) has been noted
(Arbiser et al., 2004). Thus, RDEB
SCCs and UV-associated SCCs appear
to be genetically similar.
To identify therapeutic targets in
SCC, an integrated approach to gene
expression profiling beginning with
primary keratinocytes in culture was
developed (Watt et al., 2011). The
study established candidate drivers of
SCCs by first defining a set of in vitro
cancer genes and then comparing
their expression in a range of clinical
data sets that included normal skin,
cutaneous SCCs, and psoriasis. This
analysis revealed 21 upregulated genes
that were then tested using a small
interfering RNA screen to see which of
the targets had the capacity to reduce
xenograft tumor volume in vivo. Small-
molecule inhibitors for one of the
targets, polo-like kinase-1, showed
efficacy in SCC. It is noteworthy that
polo-like kinase-1 inhibitors are already
in clinical trial for other malignancies,
thereby presenting a possible direct
translational research opportunity for
EB SCCs. Small interfering RNA–
mediated knockdown of one other target
overexpressed in SCCs, C20orf20,
induced apoptosis in vitro and reduced
SCC growth in vivo. Thus, this study
identified putative drivers of cutaneous
SCCs as potential new therapeutic
targets in treating this malignancy.
On comparing cultured fibroblasts iso-
lated from RDEB individuals without
SCC and fibroblasts directly from tumor
matrix in RDEB and non-RDEB samples,
it was shown that, although gene expres-
sion of RDEB-normal skin fibroblasts
resembled that of UV SCC–associated
fibroblasts, RDEB SCC–associated fibro-
blasts had a distinct gene expression
profile, with many of the differentially
expressed genes being involved in matrix
and cell adhesion (Ng et al., 2012).
Collectively, these observations sugges-
ted that the matrix composition in RDEB
skin forms a permissive environment for
tumor development. In line with these
observations, the combination of human
or murine RDEB fibroblasts with SCC
cells in a skin-equivalent culture model
enhanced tumor invasiveness, and
in vivo validation of these findings was
derived from chemical tumor induction
in the Col7a1 hypomorphic mice that
formed more aggressive SCCs than
control mice (V. Mittapalli, personal
communication).
Molecular therapies for EB
Gene therapy. To date, only one
proof-of-principle report has been
published (Mavilio et al., 2006). This
study involved the use of a retroviral
vector to insert the LAMB3 transgene
into autologous keratinocytes. Now
with over 6 years of follow-up, the
graft reportedly continues to express
laminin-332 at the dermal–epidermal
junction, and the skin remains mecha-
nically strong (De Luca et al., 2009).
Additional proof-of-principle studies for
somatic gene therapy in individuals with
RDEB are anticipated, but they are still
at preclinical or early clinical phases.
It should be noted that this kind of
ex vivo keratinocyte grafting approach
to gene therapy requires introduction of
the transgene, often using viral vectors
(Titeux et al., 2010). This step can be
bypassed by using keratinocytes derived
from the unaffected skin of patients with
revertant mosaicism, a natural gene
therapy encountered in different forms
of EB (Lai-Cheong et al., 2011; Pasmooij
and Jonkman, 2012). Finally, the ex vivo
gene therapy could use keratinocytes
differentiated from induced pluripotent
stem cells derived from the patient’s
own cells, but clinical applications
using this approach are yet to be
reported (Itoh et al., 2011; Tolar et al.,
2013).
Cell-based therapies. In contrast to
gene therapy for EB, clinical trials of
cell therapy have advanced further.
Wong et al. (2008) demonstrated that
a single intradermal injection of allo-
geneic fibroblasts into unblistered
RDEB skin can lead to the upregula-
tion of COL7A1 gene expression for
3–6 months, as well as increased type
VII collagen protein for 9–12 months.
The putative mechanism was postu-
lated to be an increase in mutant, but
partially functional, type VII collagen
through upregulation of heparin-binding
epidermal growth factor–like growth
factor (Nagy et al., 2011). However,
whether allogeneic fibroblasts have the
potential to improve the healing of
chronic wounds in RDEB has not yet
been reported in detail in placebo-
controlled trials. Clinical assessment of
intradermally injected allogeneic bone
marrow–derived mesenchymal stromal
cells, however, has been shown to
improve wound healing in RDEB with
de novo synthesis of type VII collagen.
In this case, the clinical improve-
ments after a single injection lasted for
4 months (Conget et al., 2010).
Systemic cell therapy for RDEB has
been assessed in a clinical trial of bone
marrow transplantation in seven indivi-
duals with RDEB (Wagner et al., 2010).
On the basis of initial murine studies
(Tolar et al., 2009), this study used
high-dose chemotherapy to immuno-
myeloablate individuals with RDEB to
allow lymphohematopoietic engraft-
ment using unfiltered bone marrow to
preserve all the hematogenous cell
populations. It should be noted that
this procedure carries a high risk of
morbidity and significant mortality, one
of the patients dying in this study from
complications before grafting. Of the six
subjects who received the infusion of
bone marrow–derived stem cells, all
demonstrated skin and marrow chimer-
ism, and five individuals showed
increased type VII collagen deposition
at the dermal–epidermal junction. All
had some degree of clinical benefit,
including the patient in whom there
was no change in type VII collagen,
and improvement that has been main-
tained in a follow-up of up to 4 years
post bone marrow transplantation (Tolar
and Wagner, 2012). Although the precise
nature of the bone marrow cells and
paracrine factors underpinning the
clinical responses remain to be
determined, further clinical trials are in
progress in a bid to minimize toxicity
L Bruckner-Tuderman et al.
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(e.g., reduced intensity conditioning and
additional infusion of mesenchymal
stromal cells) and to explore whether
other forms of EB, including Herlitz and
non-Herlitz JEB, might also show cli-
nicopathologic improvement following
bone marrow transplantation.
Protein replacement. Another innova-
tive approach to counteract blistering
in EB involves protein replacement
therapy. The initial preclinical studies
used Col7a1 / mice as a platform
and demonstrated that the injection of
purified human type VII collagen into
these RDEB mice results in the forma-
tion of anchoring fibrils and correction
of the blistering phenotype (Woodley
et al., 2004; Remington et al., 2009).
In subsequent studies, intravenous
injection of recombinant type VII colla-
gen in Col7a1 / mice was shown to
home into the wounds and restore type
VII collagen expression and function
(Woodley et al., 2013). In a model
consisting of full-thickness skin wounds
created in athymic mice, intravenously
injected human type VII collagen
homed to wound sites and incor-
porated into the dermal–epidermal junc-
tion at 2 weeks after injection. These
data suggested that protein replacement
therapy by intravenous injection of type
VII collagen could restore the dermal–
epidermal adhesion in RDEB by restor-
ing anchoring fibril formation.
On the basis of the preclinical studies
using various mouse models as a
platform, a company, Lotus Tissue
Repair (launched in 2011 and recently
acquired by Shire Pharmaceuticals), has
initiated a program with an aggressive
timeline to commercialize the clinical
application of recombinant type VII
collagen for the treatment of RDEB (M.
de Souza, personal communication).
The company is currently performing
extended animal studies using a RDEB
dog model as target, and phase I clinical
trials with FDA approval for intradermal
and intravenous delivery are expected
to follow soon. Although the prospects
of protein therapy for RDEB look
promising, careful attention needs to
be placed on monitoring the side effects,
such as development of antibodies to
type VII collagen (de Souza and Rangel
Miller, 2012).
The role of DEBRA International as a
patient-advocacy organization
DEBRA International (http://www.
DEBRA-international.org)–sponsored
Triennial Research Conferences, such as
EB2012, serve not only as a yardstick for
research progress, but also to bring
together the international EB research
community to foster new ideas and
collaborations and to set research prio-
rities. DEBRA International is the
patient-advocacy organization working
on behalf of all patients with EB and
their families worldwide, providing
patient-support services, and funding
both basic and clinical EB research.
Patient-advocacy organizations are
increasingly recognized for their role in
setting the agenda for rare-disease ther-
apy development, as exemplified by EB
(Terry et al., 2007; de Souza and Rangel
Miller, 2012). They can provide disease-
, patient-, and socioeconomic-impact
metrics, as well as direct access, to
both patient populations and clinical
specialists through clinical networks.
Numerous EB clinical research groups
are developing disease severity scores
and quality of life measures. DEBRA
brought these groups together in a
Workshop at EB2012 to derive consen-
sus and identify gaps requiring further
work. DEBRA is also supporting studies
to document the natural history of EB,
and validated clinical end points appro-
priate for therapy evaluation, and is
engaging in studies to document the
socioeconomic impact for patients with
EB and their families.
The patients’ perspective
At previous EB research conferences,
positive feedback to patients’ presenta-
tions on their experiences in clinical
trials encouraged organizers to convene
a ‘‘Patient Forum’’ at EB2012. In˜igo
Ibarrondo, a patient whose parents
founded DEBRA Espan˜a, noted that it
is sometimes difficult to grasp the pur-
pose of lengthy investigations into
apparently esoteric details when life is
a daily struggle for those whose ‘‘time is
running out’’, but that speaking directly
with researchers was valuable for under-
standing how basic research could
benefit the life of an EB patient. Also
acknowledged was the complexity of
the condition, with competition for
attention and resources with other
equally devastating diseases. The long,
hard path of research was recognized as
needing sometimes ‘‘superhuman’’
efforts, matching that of patients in their
daily lives.
‘‘You are walking and building a path
for people with EB, away from death or
struggling for lifey.Bottom line, thanks
not only for walking this path with us,
but also for us. Please keep walking.’’
(In˜igo Ibarrondo, EB Patient Forum,
EB2012).
There was a strong message from
In˜igo and the patient group that ‘‘avoid-
ing unnecessary delay’’ is urgent, but
that participation at EB2012 had engen-
dered optimism that progress is being
made in taking diverse EB therapies into
clinical trials.
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